Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 236

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 236
---
     no shares issued and outstanding at December 31, 2024 and    December 31, 2023.

    —

    —

    Common stock, $0.0001 par value; 500,000,000 shares authorized    at December 31, 2024 and December 31, 2023; 50,754,262 and    43,099,055 shares issued at December 31, 2024 and    December 31, 2023, respectively, and 50,749,945 and    43,024,634 shares outstanding at December 31, 2024 and    December 31, 2023, respectively.

    5

    4

    Additional paid-in capital

    593,687

    368,707

    Accumulated other comprehensive income

    770

    381

    Accumulated deficit

    (251,311
    )

    (164,830
    )

    Total stockholders’ equity

    343,151

    204,262

    Total liabilities and stockholders’ equity
     
    $
    363,558

    $
    225,857

 See accompanying notes to financial statements.

116

Tyra Biosciences, Inc.

Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

    Year EndedDecember 31,

    2024

    2023

    Operating expenses:

    Research and development
     
    $
    80,077

    $
    62,518

    General and administrative

    24,100

    17,427

    Total operating expenses

    104,177

    79,945

    Loss from operations

    (104,177
    )

    (79,945
    )

    Other income:

    Interest and other income, net

    17,696

    10,811

    Total other income

    17,696

    10,811

    Net loss

    (86,481
    )

    (69,134
    )

    Unrealized gain on marketable securities    available-for-sale, net

    389

    381

    Comprehensive loss
     
    $
    (86,092
    )
     
    $
    (68,753